BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Boehringer Ingelheim readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Boehringer Ingelheim's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06151574-2274@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20261210
DTEND;VALUE=DATE:20261211
SUMMARY:Hernexeos (Zongertinib): Phase 3 readout est. (NCT06151574)
DESCRIPTION:Hernexeos (Zongertinib)\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) 
 Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations 
 Compared With Standard Treatment\nEstimated primary completion: 10 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/zongertinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06151
 574
URL:https://assetmemo.bio/drug/zongertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06769048-5265@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:BI 1584862: Phase 2 readout est. (NCT06769048)
DESCRIPTION:BI 1584862\, phase 2\, Age-Related Macular Degeneration.\nStudy
 : A Study to Test Different Doses of BI 1584862 in People With a Distinct 
 Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy\n
 Estimated primary completion: 22 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/bi-1584862#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06769048
URL:https://assetmemo.bio/drug/bi-1584862#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06531824-369@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vicadrostat: Phase 3 readout est. (NCT06531824)
DESCRIPTION:Vicadrostat\, phase 3\, Chronic Kidney Disease.\nStudy: EASi-KI
 DNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combin
 ation With Empagliflozin)\nEstimated primary completion: 31 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/vicadrostat#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06531824
URL:https://assetmemo.bio/drug/vicadrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06063967-3@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT06063967)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Crohn's Disease.\nStudy: A S
 tudy to Assess Adverse Events and Change in Disease Activity of Risankizum
 ab Subcutaneous Induction Treatment for Moderately to Severely Active Croh
 n's Disease.\nEstimated primary completion: March 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/risankizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06063967
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06014528-2138@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270324
DTEND;VALUE=DATE:20270325
SUMMARY:Ifebemtinib: Phase 2 readout est. (NCT06014528)
DESCRIPTION:Ifebemtinib\, phase 2.\nStudy: IN10018 in Combination With Pegy
 lated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for 
 the Treatment of Platinum-resistant Recurrent Ovarian Cancer\nEstimated pr
 imary completion: 24 March 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ifebemtinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06014528
URL:https://assetmemo.bio/drug/ifebemtinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06806592-10645@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Nerandomilast (Jascayd): Phase 3 readout est. (NCT06806592)
DESCRIPTION:Nerandomilast (Jascayd)\, phase 3.\nStudy: A Study to Test Whet
 her Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Dis
 eases\nEstimated primary completion: 15 April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06806592
URL:https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07107945-308@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270416
DTEND;VALUE=DATE:20270417
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT07107945)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3\, Chronic Kidney Disease.\n
 Study: A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps 
 Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)\
 nEstimated primary completion: 16 April 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07107945
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06238622-10645@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:Nerandomilast (Jascayd): Phase 3 readout est. (NCT06238622)
DESCRIPTION:Nerandomilast (Jascayd)\, phase 3\, Idiopathic Pulmonary Fibros
 is.\nStudy: A Follow-up Study to Test Long-term Treatment With Nerandomila
 st in People With Pulmonary Fibrosis Who Took Part in a Previous Study Wit
 h Nerandomilast\nEstimated primary completion: 28 April 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06238622
URL:https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662122-153@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270626
DTEND;VALUE=DATE:20270627
SUMMARY:BI 3034701: Phase 2 readout est. (NCT07662122)
DESCRIPTION:BI 3034701\, phase 2\, Obesity.\nStudy: A Study to Test Whether
  BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweigh
 t\nEstimated primary completion: 26 June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/bi-3034701#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07662122
URL:https://assetmemo.bio/drug/bi-3034701#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06636656-43@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:BI 3032950: Phase 2 readout est. (NCT06636656)
DESCRIPTION:BI 3032950\, phase 2\, Ulcerative Colitis.\nStudy: A Study to T
 est Whether BI 3032950 Helps People With Ulcerative Colitis\nEstimated pri
 mary completion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/bi-3032950#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06636656
URL:https://assetmemo.bio/drug/bi-3032950#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880744-3@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT06880744)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Ulcerative Colitis.\nStudy: 
 A Study to Assess the Change in Disease Activity in Adult Participants Wit
 h Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared
  to Vedolizumab\nEstimated primary completion: August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06880744
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486817-2274@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270812
DTEND;VALUE=DATE:20270813
SUMMARY:Hernexeos (Zongertinib): Phase 2 readout est. (NCT07486817)
DESCRIPTION:Hernexeos (Zongertinib)\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Beamion 44: A Study to Test How Well Zongertinib is Tolerated by 
 People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When G
 iven in Combination With Chemotherapy With or Without Pembrolizumab\nEstim
 ated primary completion: 12 August 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/zongertinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07486817
URL:https://assetmemo.bio/drug/zongertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03886246-42@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Spevigo (spesolimab): Phase 2 readout est. (NCT03886246)
DESCRIPTION:Spevigo (spesolimab)\, phase 2\, Psoriasis.\nStudy: Effisayil
 ™ ON: A Study to Test Long-term Treatment With Spesolimab in People With
  Generalized Pustular Psoriasis Who Took Part in a Previous Study\nEstimat
 ed primary completion: 30 September 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/spesolimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT03886246
URL:https://assetmemo.bio/drug/spesolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06624670-42@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20271112
DTEND;VALUE=DATE:20271113
SUMMARY:Spevigo (spesolimab): Phase 3 readout est. (NCT06624670)
DESCRIPTION:Spevigo (spesolimab)\, phase 3.\nStudy: A Study to Test Whether
  Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
 \nEstimated primary completion: 12 November 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/spesolimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06624670
URL:https://assetmemo.bio/drug/spesolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05882058-7739@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20271217
DTEND;VALUE=DATE:20271218
SUMMARY:Obrixtamig: Phase 2 readout est. (NCT05882058)
DESCRIPTION:Obrixtamig\, phase 2\, Small Cell Lung Cancer.\nStudy: DAREON
 ™-5: A Study to Test Whether Different Doses of BI 764532 Help People Wi
 th Small Cell Lung Cancer or Other Neuroendocrine Cancers\nEstimated prima
 ry completion: 17 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/obrixtamig#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05882058
URL:https://assetmemo.bio/drug/obrixtamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06166836-2138@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ifebemtinib: Phase 1/2 readout est. (NCT06166836)
DESCRIPTION:Ifebemtinib\, phase 1/2.\nStudy: a Study to Evaluate the Safety
  and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tu
 mors\nEstimated primary completion: 31 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ifebemtinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06166836
URL:https://assetmemo.bio/drug/ifebemtinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07754461-119@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20280117
DTEND;VALUE=DATE:20280118
SUMMARY:survodutide: Phase 3 readout est. (NCT07754461)
DESCRIPTION:survodutide\, phase 3\, Type 2 Diabetes.\nStudy: A Study to Tes
 t Whether Survodutide Helps People With Type 2 Diabetes Control Their Bloo
 d Sugar\nEstimated primary completion: 17 January 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/survodutide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07754461
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07355296-902@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20280120
DTEND;VALUE=DATE:20280121
SUMMARY:Apecotrep: Phase 2 readout est. (NCT07355296)
DESCRIPTION:Apecotrep\, phase 2\, Chronic Kidney Disease.\nStudy: PODOMOUNT
 -Basket\, a Study to Test Whether BI 764198 Helps Adults and Adolescents W
 ith Different Types of Kidney Disease\nEstimated primary completion: 20 Ja
 nuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apecotrep
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073
 55296
URL:https://assetmemo.bio/drug/apecotrep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04524611-3@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT04524611)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Crohn's Disease.\nStudy: Stu
 dy Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Uste
 kinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult
  Participants With Moderate to Severe Crohn's Disease (CD)\nEstimated prim
 ary completion: February 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/risankizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04524611
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06962839-5344@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:BI 1815368: Phase 2 readout est. (NCT06962839)
DESCRIPTION:BI 1815368\, phase 2\, Diabetic Macular Edema.\nStudy: A Study 
 to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabe
 tic Macular Edema\nEstimated primary completion: 1 March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/bi-1815368#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06962839
URL:https://assetmemo.bio/drug/bi-1815368#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04862286-3@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT04862286)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Psoriasis.\nStudy: Study to 
 Evaluate Adverse Events and Change in Disease Activity in Participants Bet
 ween 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With 
 Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participati
 on in Study M19-977\nEstimated primary completion: April 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04862286
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06424288-369@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20280522
DTEND;VALUE=DATE:20280523
SUMMARY:Vicadrostat: Phase 3 readout est. (NCT06424288)
DESCRIPTION:Vicadrostat\, phase 3\, Heart Failure.\nStudy: A Study to Test 
 Whether Vicadrostat in Combination With Empagliflozin Helps People With He
 art Failure\nEstimated primary completion: 22 May 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/vicadrostat#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06424288
URL:https://assetmemo.bio/drug/vicadrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07929051-7739@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20280703
DTEND;VALUE=DATE:20280704
SUMMARY:Obrixtamig: Phase 3 readout est. (NCT07929051)
DESCRIPTION:Obrixtamig\, phase 3.\nStudy: A Study to Test Obrixtamig Treatm
 ent in People With Different Types of Advanced Cancer Who Took Part in a P
 revious Study With Obrixtamig\nEstimated primary completion: 3 July 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/obrixtamig#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07929051
URL:https://assetmemo.bio/drug/obrixtamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850050-119@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20280726
DTEND;VALUE=DATE:20280727
SUMMARY:survodutide: Phase 3 readout est. (NCT07850050)
DESCRIPTION:survodutide\, phase 3\, Obesity.\nStudy: SYNCHRONIZE®-HERA: A 
 Study to Test Whether Survodutide Helps Women Who Are Living With Overweig
 ht or Obesity and Are Going Through or Have Finished Menopause\, to Lose W
 eight\nEstimated primary completion: 26 July 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/survodutide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07850050
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03398135-3@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT03398135)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Ulcerative Colitis.\nStudy: 
 A Study to Assess the Efficacy and Safety of Risankizumab in Participants 
 With Ulcerative Colitis\nEstimated primary completion: September 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03398135
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07174908-2138@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Ifebemtinib: Phase 3 readout est. (NCT07174908)
DESCRIPTION:Ifebemtinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy
  for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mut
 ation\nEstimated primary completion: September 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ifebemtinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07174908
URL:https://assetmemo.bio/drug/ifebemtinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472517-7739@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20280909
DTEND;VALUE=DATE:20280910
SUMMARY:Obrixtamig: Phase 3 readout est. (NCT07472517)
DESCRIPTION:Obrixtamig\, phase 3\, Small Cell Lung Cancer.\nStudy: DAREON 
 ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Comp
 are Obrixtamig Plus Atezolizumab\, Carboplatin\, and Etoposide Treatment W
 ith Standard Chemoimmunotherapy\nEstimated primary completion: 9 September
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/obrixtamig#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0747251
 7
URL:https://assetmemo.bio/drug/obrixtamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06581432-2274@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Hernexeos (Zongertinib): Phase 2 readout est. (NCT06581432)
DESCRIPTION:Hernexeos (Zongertinib)\, phase 2.\nStudy: Beamion PANTUMOR-1: 
 A Study to Test Whether Zongertinib Helps People With Advanced Cancers Wit
 h HER2 Alterations\nEstimated primary completion: 30 November 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/zongertinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06581432
URL:https://assetmemo.bio/drug/zongertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07540988-10645@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20281205
DTEND;VALUE=DATE:20281206
SUMMARY:Nerandomilast (Jascayd): Phase 3 readout est. (NCT07540988)
DESCRIPTION:Nerandomilast (Jascayd)\, phase 3.\nStudy: FIBRONEER-ACT: A Stu
 dy to Test Whether Nerandomilast Helps People With Fibrosing Interstitial 
 Lung Disease at Risk for Disease Progression\nEstimated primary completion
 : 5 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ne
 randomilast-jascayd#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07540988
URL:https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220083-902@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20281227
DTEND;VALUE=DATE:20281228
SUMMARY:Apecotrep: Phase 3 readout est. (NCT07220083)
DESCRIPTION:Apecotrep\, phase 3\, Chronic Kidney Disease.\nStudy: A Study t
 o Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Conditi
 on Called Focal Segmental Glomerulosclerosis (FSGS)\nEstimated primary com
 pletion: 27 December 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/apecotrep#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07220083
URL:https://assetmemo.bio/drug/apecotrep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06324357-2274@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20290108
DTEND;VALUE=DATE:20290109
SUMMARY:Hernexeos (Zongertinib): Phase 1/2 readout est. (NCT06324357)
DESCRIPTION:Hernexeos (Zongertinib)\, phase 1/2.\nStudy: Beamion BCGC-1: A 
 Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination
  With Other Treatments to Test Whether it Helps People With Different Type
 s of HER2+ Cancer That Has Spread\nEstimated primary completion: 8 January
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/zongertinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT063243
 57
URL:https://assetmemo.bio/drug/zongertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03105102-3@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT03105102)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Crohn's Disease.\nStudy: A S
 tudy of the Efficacy and Safety of Risankizumab in Participants With Crohn
 's Disease\nEstimated primary completion: February 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/risankizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03105102
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07409181-5598@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20290204
DTEND;VALUE=DATE:20290205
SUMMARY:BI 3000202: Phase 2 readout est. (NCT07409181)
DESCRIPTION:BI 3000202\, phase 2\, Systemic Lupus Erythematosus.\nStudy: A 
 Study to Test Whether Different Doses of BI 3000202 Help People With Syste
 mic Lupus Erythematosus (SLE)\nEstimated primary completion: 4 February 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/bi-3000202#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07409181
URL:https://assetmemo.bio/drug/bi-3000202#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06935370-369@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20290204
DTEND;VALUE=DATE:20290205
SUMMARY:Vicadrostat: Phase 3 readout est. (NCT06935370)
DESCRIPTION:Vicadrostat\, phase 3\, Heart Failure.\nStudy: A Study to Test 
 Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps Pe
 ople With Heart Failure and a Weak Pumping Function of the Left Side of th
 e Heart\nEstimated primary completion: 4 February 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/vicadrostat#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06935370
URL:https://assetmemo.bio/drug/vicadrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05995353-3@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT05995353)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Crohn's Disease.\nStudy: A S
 tudy to Assess Adverse Events\, Change in Disease Activity\, and How Intra
 venous and Subcutaneous Risankizumab Moves Through the Body of Pediatric P
 articipants With Moderately to Severely Active Crohn's Disease\nEstimated 
 primary completion: April 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/risankizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05995353
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07366034-10645@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20290427
DTEND;VALUE=DATE:20290428
SUMMARY:Nerandomilast (Jascayd): Phase 3 readout est. (NCT07366034)
DESCRIPTION:Nerandomilast (Jascayd)\, phase 3.\nStudy: A Study to Find Out 
 How Nerandomilast is Tolerated\, Handled by the Body\, and if it Helps Chi
 ldren and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)\nEs
 timated primary completion: 27 April 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07366034
URL:https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850063-119@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20290429
DTEND;VALUE=DATE:20290430
SUMMARY:survodutide: Phase 3 readout est. (NCT07850063)
DESCRIPTION:survodutide\, phase 3\, Obesity.\nStudy: ELEVATE-LIVER: A Study
  to Test Whether Survodutide Helps Improve Heart Structure and Function in
  People With Overweight or Obesity and Fatty Liver Disease\nEstimated prim
 ary completion: 29 April 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/survodutide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07850063
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07201922-10645@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20290514
DTEND;VALUE=DATE:20290515
SUMMARY:Nerandomilast (Jascayd): Phase 3 readout est. (NCT07201922)
DESCRIPTION:Nerandomilast (Jascayd)\, phase 3.\nStudy: A Study to Test Whet
 her Nerandomilast Can Help Slow Down Changes in the Lung in People With a 
 Family History of Pulmonary Fibrosis\nEstimated primary completion: 14 May
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/nerandomilast-
 jascayd#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07201922
URL:https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632457-119@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20290605
DTEND;VALUE=DATE:20290606
SUMMARY:survodutide: Phase 3 readout est. (NCT06632457)
DESCRIPTION:survodutide\, phase 3\, MASH / NASH.\nStudy: LIVERAGE™ - Cirr
 hosis: A Study to Test Whether Survodutide Helps People With a Liver Disea
 se Called NASH/MASH Who Have Cirrhosis\nEstimated primary completion: 5 Ju
 ne 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/survodutide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0663
 2457
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06865105-3@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Skyrizi (risankizumab): Phase 2 readout est. (NCT06865105)
DESCRIPTION:Skyrizi (risankizumab)\, phase 2\, Psoriatic Arthritis.\nStudy:
  Study of Targeted Therapies for the Treatment of Adult Participants With 
 Active Psoriatic Arthritis\nEstimated primary completion: August 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06865105
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07855900-119@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20291106
DTEND;VALUE=DATE:20291107
SUMMARY:survodutide: Phase 3 readout est. (NCT07855900)
DESCRIPTION:survodutide\, phase 3\, Obesity.\nStudy: SYNCHRONIZE®-START- A
  Study to Test Whether Survodutide Helps People Living With Overweight or 
 Obesity Who do Not Have Diabetes to Lose Weight\nEstimated primary complet
 ion: 6 November 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /survodutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07855900
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07544654-7739@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20291213
DTEND;VALUE=DATE:20291214
SUMMARY:Obrixtamig: Phase 3 readout est. (NCT07544654)
DESCRIPTION:Obrixtamig\, phase 3.\nStudy: DAREON®-NEC-1: A Study in People
  With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obr
 ixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherap
 y\nEstimated primary completion: 13 December 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/obrixtamig#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07544654
URL:https://assetmemo.bio/drug/obrixtamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07064473-369@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20291214
DTEND;VALUE=DATE:20291215
SUMMARY:Vicadrostat: Phase 3 readout est. (NCT07064473)
DESCRIPTION:Vicadrostat\, phase 3\, Type 2 Diabetes.\nStudy: EASi-PROTKT™
  - A Study to Test Vicadrostat (BI 690517) Taken Together With Empaglifloz
 in in People With Type 2 Diabetes\, High Blood Pressure\, and Cardiovascul
 ar Disease\nEstimated primary completion: 14 December 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/vicadrostat#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07064473
URL:https://assetmemo.bio/drug/vicadrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06548542-3@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Skyrizi (risankizumab): Phase 2 readout est. (NCT06548542)
DESCRIPTION:Skyrizi (risankizumab)\, phase 2\, Crohn's Disease.\nStudy: Stu
 dy of Targeted Therapies for the Treatment of Adult Participants With Mode
 rate to Severe Crohn's Disease\nEstimated primary completion: January 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06548542
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07497087-10645@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20300226
DTEND;VALUE=DATE:20300227
SUMMARY:Nerandomilast (Jascayd): Phase 3 readout est. (NCT07497087)
DESCRIPTION:Nerandomilast (Jascayd)\, phase 3\, Systemic Sclerosis.\nStudy:
  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosi
 s\nEstimated primary completion: 26 February 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07497087
URL:https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07789015-10645@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20300321
DTEND;VALUE=DATE:20300322
SUMMARY:Nerandomilast (Jascayd): Phase 3 readout est. (NCT07789015)
DESCRIPTION:Nerandomilast (Jascayd)\, phase 3.\nStudy: A Study to Understan
 d How Nerandomilast Works in People With Active Idiopathic Inflammatory My
 opathies\nEstimated primary completion: 21 March 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07789015
URL:https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843940-7739@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20300417
DTEND;VALUE=DATE:20300418
SUMMARY:Obrixtamig: Phase 1/2 readout est. (NCT07843940)
DESCRIPTION:Obrixtamig\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Stud
 y to Test Obrixtamig in Combination With Pumitamig in People With Advanced
  Small Cell Lung Cancer (Dareon®-Rosetta35)\nEstimated primary completion
 : 17 April 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obri
 xtamig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07843940
URL:https://assetmemo.bio/drug/obrixtamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07707895-7739@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20300426
DTEND;VALUE=DATE:20300427
SUMMARY:Obrixtamig: Phase 1/2 readout est. (NCT07707895)
DESCRIPTION:Obrixtamig\, phase 1/2\, Small Cell Lung Cancer.\nStudy: DAREON
 ®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People Wi
 th Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers\nEstima
 ted primary completion: 26 April 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/obrixtamig#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07707895
URL:https://assetmemo.bio/drug/obrixtamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441174-2138@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Ifebemtinib: Phase 1/2 readout est. (NCT07441174)
DESCRIPTION:Ifebemtinib\, phase 1/2.\nStudy: IN10018 in Combination With RN
 K08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or
  Metastatic Solid Tumors\nEstimated primary completion: 28 February 2031. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ifebemtinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07441174
URL:https://assetmemo.bio/drug/ifebemtinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07697456-3@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Skyrizi (risankizumab): Phase 2 readout est. (NCT07697456)
DESCRIPTION:Skyrizi (risankizumab)\, phase 2\, Ulcerative Colitis.\nStudy: 
 Study of Advanced Therapies for the Treatment of Adult Participants With M
 oderately to Severely Active Crohn's Disease or Ulcerative Colitis\nEstima
 ted primary completion: October 2031. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/risankizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07697456
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632444-119@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20311227
DTEND;VALUE=DATE:20311228
SUMMARY:survodutide: Phase 3 readout est. (NCT06632444)
DESCRIPTION:survodutide\, phase 3\, MASH / NASH.\nStudy: LIVERAGE™: A Stu
 dy to Test Whether Survodutide Helps People With a Liver Disease Called NA
 SH/MASH Who Have Moderate or Advanced Liver Fibrosis\nEstimated primary co
 mpletion: 27 December 2031. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/survodutide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06632444
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07195695-2274@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20320226
DTEND;VALUE=DATE:20320227
SUMMARY:Hernexeos (Zongertinib): Phase 3 readout est. (NCT07195695)
DESCRIPTION:Hernexeos (Zongertinib)\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in Peo
 ple With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2
  TKD Mutations\nEstimated primary completion: 26 February 2032. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/zongertinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07195695
URL:https://assetmemo.bio/drug/zongertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071519-3@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20340731
DTEND;VALUE=DATE:20340801
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT07071519)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Ulcerative Colitis.\nStudy: 
 A Study to Learn More About How Risankizumab Works in Young Participants W
 ith Ulcerative Colitis\nEstimated primary completion: July 2034. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07071519
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
